Voyager Therapeutics, Inc. Forecast, price target & analysts
Voyager Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Voyager Therapeutics, Inc. Classifications & Recommendation
Voyager Therapeutics, Inc. Price Target
| Target Price | $12.24 |
| Price | $2.80 |
| Potential |
337.14%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Voyager Therapeutics, Inc. 2027 .
The average Voyager Therapeutics, Inc. target price is $12.24.
This is
337.14%
register free of charge
$26.25
837.50%
register free of charge
$8.08
188.57%
register free of charge
|
|
| A rating was issued by 17 analysts: 16 Analysts recommend Voyager Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Voyager Therapeutics, Inc. stock has an average upside potential 2027 of
337.14%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 40.37 | 20.69 |
| 49.54% | 48.75% | |
| EBITDA Margin | -316.52% | -494.74% |
| 234.24% | 56.31% | |
| Net Margin | -296.56% | -502.24% |
| 264.99% | 69.36% |
13 Analysts have issued a sales forecast Voyager Therapeutics, Inc. 2026 . The average Voyager Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Voyager Therapeutics, Inc. EBITDA forecast 2026. The average Voyager Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Voyager Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Voyager Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.04 | -1.70 |
| 80.53% | 16.67% | |
| P/E | negative | |
| EV/Sales | 2.75 |
13 Analysts have issued a Voyager Therapeutics, Inc. forecast for earnings per share. The average Voyager Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Voyager Therapeutics, Inc....
Current Voyager Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 17 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 17 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 15 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
